share_log

Adial Pharmaceuticals | S-3: Registration statement for specified transactions by certain issuers

Adial Pharmaceuticals | S-3: Registration statement for specified transactions by certain issuers

Adial Pharmaceuticals | S-3：特定交易註冊聲明
美股sec公告 ·  04/12 16:28
Moomoo AI 已提取核心訊息
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, has filed a registration statement with the Securities and Exchange Commission (SEC) on April 12, 2024, for a Form S-3 registration statement under the Securities Act of 1933. This filing pertains to the resale of up to 2,369,000 shares of common stock by Selling Stockholders, which includes shares issuable upon the exercise of Series C Common Warrants and Placement Agent Warrants. The Selling Stockholders include certain investors and designees of H.C. Wainwright & Co., LLC, the placement agent in connection with a private placement transaction that closed on March 6, 2024. The registration of these shares does not necessarily mean that the Selling Stockholders will sell their shares, nor does it guarantee that any proceeds from the sale will be received by Adial Pharmaceuticals. The company's common stock is listed on the Nasdaq Capital Market under the symbol 'ADIL'. The filing of this registration statement is part of Adial Pharmaceuticals' contractual obligations to provide for the resale by the Selling Stockholders of the shares of common stock offered.
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, has filed a registration statement with the Securities and Exchange Commission (SEC) on April 12, 2024, for a Form S-3 registration statement under the Securities Act of 1933. This filing pertains to the resale of up to 2,369,000 shares of common stock by Selling Stockholders, which includes shares issuable upon the exercise of Series C Common Warrants and Placement Agent Warrants. The Selling Stockholders include certain investors and designees of H.C. Wainwright & Co., LLC, the placement agent in connection with a private placement transaction that closed on March 6, 2024. The registration of these shares does not necessarily mean that the Selling Stockholders will sell their shares, nor does it guarantee that any proceeds from the sale will be received by Adial Pharmaceuticals. The company's common stock is listed on the Nasdaq Capital Market under the symbol 'ADIL'. The filing of this registration statement is part of Adial Pharmaceuticals' contractual obligations to provide for the resale by the Selling Stockholders of the shares of common stock offered.
臨床階段的生物製藥公司Adial Pharmaceuticals, Inc. 已於2024年4月12日向美國證券交易委員會（SEC）提交了根據1933年《證券法》提交了S-3表格註冊聲明的註冊聲明。該文件涉及賣方股東轉售最多2369,000股普通股，其中包括行使C系列普通認股權證和配售代理認股權證時可發行的股票。出售股東包括H.C. Wainwright & Co., LLC的某些投資者和指定人。H.C. Wainwright & Co., LLC是與2024年3月6日完成的私募交易相關的配售代理人。這些股票的註冊並不一定意味着賣出股東將出售其股份，也不保證Adial Pharmicals會收到任何出售收益。該公司的普通股在納斯達克資本市場上市，股票代碼爲 “ADIL”。本註冊聲明的提交是Adial Pharmaceuticals合同義務的一部分，該義務要求賣出股東轉售所發行的普通股。
臨床階段的生物製藥公司Adial Pharmaceuticals, Inc. 已於2024年4月12日向美國證券交易委員會（SEC）提交了根據1933年《證券法》提交了S-3表格註冊聲明的註冊聲明。該文件涉及賣方股東轉售最多2369,000股普通股，其中包括行使C系列普通認股權證和配售代理認股權證時可發行的股票。出售股東包括H.C. Wainwright & Co., LLC的某些投資者和指定人。H.C. Wainwright & Co., LLC是與2024年3月6日完成的私募交易相關的配售代理人。這些股票的註冊並不一定意味着賣出股東將出售其股份，也不保證Adial Pharmicals會收到任何出售收益。該公司的普通股在納斯達克資本市場上市，股票代碼爲 “ADIL”。本註冊聲明的提交是Adial Pharmaceuticals合同義務的一部分，該義務要求賣出股東轉售所發行的普通股。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息